3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis

Authors :: Richard B Warren
Kristian Reich
Eric L Simpson
Richard Langley
Antonio Costanzo
Hidehisa Saeki
Peter Almgren
Emilia Vacko
Melinda Gooderham
Mette Deleuran
Juan Francisco Silvestre
Stefan Weidinger
Andrew Blauvelt
Source :: SKIN The Journal of Cutaneous Medicine. 6:s78
Publication Year :: 2022
Publisher :: National Society for Cutaneous Medicine, 2022.

Tools